Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
37.19
-1.01 (-2.64%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Edgewise Therapeutics Employees
Edgewise Therapeutics had 127 employees as of June 30, 2026. The number of employees increased by 1 or 0.79% compared to the same quarter last year. That makes Edgewise Therapeutics the 29,925th largest employer in the world and 3,835th in the United States.
Employees
127
Change
1
Growth
0.79%
Revenue / Employee
n/a
Profits / Employee
-$1,552,929
Market Cap
4.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 127 | 1 | 0.79% |
| Mar 31, 2026 | 154 | 37 | 31.62% |
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Sep 30, 2025 | 136 | 28 | 25.93% |
| Jun 30, 2025 | 126 | 29 | 29.90% |
| Mar 31, 2025 | 117 | 25 | 27.17% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Sep 30, 2024 | 108 | 28 | 35.00% |
| Jun 30, 2024 | 97 | 23 | 31.08% |
| Mar 31, 2024 | 92 | 25 | 37.31% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Sep 30, 2023 | 80 | 30 | 60.00% |
| Jun 30, 2023 | 74 | 32 | 76.19% |
| Mar 31, 2023 | 67 | 29 | 76.32% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Sep 30, 2022 | 50 | 20 | 66.67% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Mar 31, 2022 | 38 | 16 | 72.73% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| AbCellera Biologics | 562 |
| CRISPR Therapeutics AG | 393 |
| Arcutis Biotherapeutics | 354 |
| Scholar Rock Holding | 289 |
| Relay Therapeutics | 202 |
| Tango Therapeutics | 137 |
EWTX News
- 1 day ago - Edgewise Therapeutics initiated with an Outperform at William Blair - TheFly
- 9 days ago - Edgewise Therapeutics doses first patient in Phase 2 trial of EDG-15400 - TheFly
- 9 days ago - Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 - PRNewsWire
- 16 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 25 days ago - Edgewise Therapeutics Transcript: Study update - Transcripts
- 25 days ago - Edgewise Therapeutics Slides: Study update - Filings
- 25 days ago - Edgewise Therapeutics Press release: Study update - Filings
- 25 days ago - Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 - PRNewsWire